CNSP News and Press, CNS Pharmaceuticals Inc. From 09/28/22

CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM PR Newswire Sites in France and Spain now open and actively enrolling Enrollment ...

Endometriosis is a disorder that causes the tissue that lines the inside of the uterus to grow outside the reproductive organ. It is associated with menstrual irregularities and pain and is estimated to affect around 10% of American women of reproductive age. The condition develops into en...

CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) PR Newswire Live moderated video webcast with Management to discuss potentially pivotal global study of lead ass...

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each year The current standard of care for GBM is ineffective for...

CNS Pharmaceuticals (NASDAQ: CNSP) , a preclinical stage biotechnology company, is looking to fill a gap in the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of cancer that occurs in the brain or spinal cord, with its lead product candidate Berubicin. ȁ...

Glioblastoma is an aggressive cancer that usually occurs in the spinal cord or the brain. While this cancer can occur at any age, it is more common in adults. The average life expectancy for patients with this type of cancer is between 12 to 15 months. Figures from the Glioblastoma Foundat...

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomas Glioblastoma is an incurable brain cancer that is aggressive in its progression and ...

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans eac...

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million The company clos...

Tumors remain one of the deadliest diseases in the world, accounting for around one in six deaths globally in 2020. While scientists may not have found a cure for life-threatening tumors despite decades of research, there are a variety of treatments that can reduce and even eliminate tumor...